Document is current

Article History

Received: 9 July 2024

Accepted: 22 August 2024

First Online: 17 October 2024

Competing interests

: Under a license agreement between Corrie Health and the Johns Hopkins University, the university owns equity in Corrie Health. F.A.M. and S.S.M. are entitled to royalty distributions related to the technology. Additionally, S.S.M. and F.A.M. are cofounders of and hold equity in Corrie Health. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. In addition, F.A.M. and S.S.M. have received material support for research from Apple and iHealth. S.S.M. is on the Advisory Board for Care Access and reports personal consulting fees from Amgen, Arrowhead, AstraZeneca, BMS, Chroma, HeartFlow, Kaneka, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Premier, Sanofi, 89bio, and Verve Therapeutics. S.S.M. reports research support from the American Heart Association Health Technologies and Innovation Strategically Focused Research Network (20SFRN35380046, 20SFRN35490003), a collaborative project of this network (#878924), and additional American Heart Association support (#882415, #946222). He also reports support from the Patient-Centered Outcomes Research Institute (ME-2019C1-15 328, IHS-2021C3-24147), the National Institutes of Health (NIH) (P01 HL108800 and R01AG071032), the David and June Trone Family Foundation, the Pollin Digital Innovation Fund, Sandra and Larry Small, Google, and Merck. F.A.M. reports personal consulting fees from Apple, Amgen, and Kaneka. The other authors declare no competing interests.